The path to PAT: the role of process analytical technologies in advancing CAR-T therapy production
Year: 2025
Type: article
Abstract: This article is part of our ‘Rising Stars’ series, giving a platform to the emerging leaders of the sector. In this series, we share the perspectives of fledgling thought-leaders, chosen by our Editorial Advisory Board members as future stars in their field. John Moscariello, Chief Technical Officer at Neuvogen Therapeutics, had this to say about his Rising Star nominee: 'Almost immediately upon the approval of the first gene-modified cell therapy products, process developers asked how we can make the product cheaper. While this emphasis has led to significant advances in automation, many people have missed what I think is a more impactful question—how can we make products with better clinical outcomes? Sarah Rajani is the industry-leader in developing adaptive cell therapy processes in which real-time measurements of cell attributes can be used to change process conditions.'
Source: Cell and Gene Therapy Insights
Author: Sarah Rajani
Institution: Bristol-Myers Squibb (United States)
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7115189346
FWCI:
Cites:
Cited by:
Related to: